Aquestive Therapeutics (AQST) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed CorMedix (CRMD) over the past year, losing 39.5% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -45.7% for AQST. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $419.2 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs -22.6%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -188.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | CRMD |
|---|---|---|
| Share price | $3.46 | $5.27 |
| Market cap | $434.88M | $419.16M |
| 1-day change | -6.61% | +3.74% |
| YTD return | -46.44% | -54.69% |
| 1-year return | -39.51% | -45.56% |
| 5-year return | -45.68% | +3.94% |
| P/E ratio (TTM) | — | 8.23 |
| Forward P/E | — | 15.06 |
| EPS (TTM) | $-0.65 | $0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.55M | $311.71M |
| Revenue growth (YoY) | -22.61% | +617.03% |
| Net income (latest FY) | $-83.78M | $163.06M |
| Gross margin | 58.35% | 88.46% |
| Operating margin | -159.50% | 48.17% |
| Net margin | -188.09% | 52.31% |
| 52-week high | $6.74 | $13.02 |
| 52-week low | $2.93 | $4.47 |
| Distance from 52-week high | -48.63% | -59.52% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +169.65% | +161.86% |
| Average volume | 2.41M | 1.44M |
| Shares outstanding | 125.69M | 79.54M |
| Employees | 147 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -22.61%).
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
AQST vs CRMD FAQ
Which is bigger, Aquestive Therapeutics or CorMedix?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $419.16M for CorMedix (CRMD).
Which stock has performed better over the past year, AQST or CRMD?
AQST returned -39.51% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.